期刊文献+

2 654例无创产前基因检测结果分析 被引量:12

Analysis of 2 654 cases of non invasive prenatal genetic test results
下载PDF
导出
摘要 目的探讨无创产前基因检测在胎儿染色体非整倍体疾病诊断中的临床应用价值。方法选择在该院行胎儿染色体非整倍体无创基因检测的单胎孕妇2 654例,对孕妇外周血中游离DNA进行高通量测序,对检测结果高风险者进行羊膜腔穿刺及胎儿染色体核型分析,对检测结果阴性者进行电话随访。结果 2 654例孕妇无创基因检测结果高风险29例,包括21-三体14例,18-三体6例,47,XXY 5例,45,XO 2例,常染色体异常1例,母体染色体异常1例。对29例高风险孕妇行羊膜腔穿刺羊水细胞染色体核型分析,结果显示21-三体11例,18-三体5例,性染色体异常4例。结论无创产前基因检测在诊断胎儿染色体非整倍体异常有较高的特异性和准确性,有较高的临床应用价值,但存在一定的假阳性,应掌握指征。 Objective To explore the clinical value of noninvasive prenatal genetic testing in diagnosis of fetal chromosomal non‐integral disease .Methods A total of 2 654 pregnant women receiving fetal chromosomal aneuploidy noninvasive prenatal genetic testing in the hospital were selected ,high‐throughput sequencing of free DNA in peripheral blood of pregnant women was conduc‐ted ,amniocentesis and fetal karyotyping were carried out among the high risk pregnant women ,the negative pregnant women were followed up by telephone .Results Among 2 654 pregnant women ,29 high risk pregnant women were found by noninvasive prenatal genetic testing ,including 14 cases with trisomy 21 ,6 cases with trisomy 18 ,5 cases with 47 ,XXY ,2 cases with 45 ,XO ,1 cases with abnormal chromosome ,1 cases with maternal chromosome abnormalities .29 cases of high‐risk pregnant women with amniotic fluid cell chromosome karyotype analysis ,the results show that 11 cases with trisomy 21 ,5 cases with trisomy 18 ,4 cases with sex chro‐mosome abnormalities .Conclusion Noninvasive prenatal genetic testing in the diagnosis of fetal chromosomal abnormalities has a high specificity and accuracy ,there is a high clinical value ,but there are some false positive ,should grasp the indications .
出处 《检验医学与临床》 CAS 2016年第23期3283-3286,共4页 Laboratory Medicine and Clinic
基金 甘肃省卫生行业科研计划资助项目(GSWST2011-12)
关键词 无创产前基因检测 染色体非整倍体 高通量测序技术 noninvasive prenatal genetic testing chromosomal aneuploidy high-throughput sequencing
  • 相关文献

参考文献3

二级参考文献35

  • 1Eloranta ML, Heinonen S, Kirkinen P. Intrahepatic cholestasis of pregnancy has no effect on maternal serum second trimester alpha-fetoprotein and HCG [ J]. Acta-Obstet Gynecol Scand, 2000, 79(6) : 548 -552.
  • 2Summers AM, Farrell SA, Huang T, et al. Maternal serum screening in ontario using the triple marker test [ J ]. J Med Screen, 2003,10 (2) :107 -111.
  • 3Wald N J, Kennard A, Hackshaw A, et al. Antenatal screening for Down's syndrome [J ] . J Med Screen, 1997,4(2) :181 -246.
  • 4Cuckle HS, Vanlith JM. App rop ridte biochemical parameters in first-trimester screening for Down syndrome [ J ]. Prenat Diagn, 1999, 19(6) : 505 -512.
  • 5Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNAsequencing of maternal plasma to detect Down syndrome: aninternational clinical validation study[J]. Genet Med, 2011,13:913-920.
  • 6Skirton H, Patch C. Factors affecting the clinical use ofnon-invasive prenatal testing: a mixed methods systematicreview[J], Prenat Diagn, 2013, 33:532-541.
  • 7American College of Obstetricians and GynecologistsCommittee on Genetics. Committee Opinion No.545:Noninvasive prenatal testing for fetal aneuploidy [J]. ObstetGynecol, 2012, 120:1532-1534.
  • 8Shaw SW, Hsiao CH, Chen CY, et al. Noninvasive prenataltesting for whole fetal chromosomal aneuploidies: a multicenterprospective cohort trial in Taiwan[J]. Fetal Diagn Ther, 2014,35:13-17.
  • 9Song Y, Liu C, Qi H, et al. Noninvasive prenatal testing of fetalaneuploidies by massively parallel sequencing in a prospectiveChinese population[J]. Prenat Diagn, 2013, 33:700-706.
  • 10Benti P, Cuckle H, Pergament E. Non-invasive prenataltesting for aneuploidy: current status and future prospects[J].Ultrasound Obstet Gynecol, 2013,42:15-33.

共引文献93

同被引文献79

引证文献12

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部